瑞舒伐他汀和阿托伐他汀对老年冠心病患者血脂、超敏C反应蛋白、同型半胱氨酸水平及颈动脉内膜中层厚度的影响

发布时间：2018-05-19 09:17

本文选题：瑞舒伐他汀 + 阿托伐他汀　；参考：《中国老年学杂志》2017年17期

【摘要】：目的比较瑞舒伐他汀和阿托伐他汀对老年冠心病患者血脂、超敏C反应蛋白(hs-CRP)、同型半胱氨酸(Hcy)及颈动脉内膜中层厚度(IMT)的影响。方法 127例老年冠心病患者随机分为A组65例、B组62例,A组给予瑞舒伐他汀治疗,B组给予阿托伐他汀治疗,比较两组患者治疗前、治疗后6、12个月总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、hs-CRP、Hcy、肿瘤坏死因子(TNF)-α、IMT及血管内皮功能变化情况,并记录患者治疗期间药物相关不良反应发生情况。结果治疗后6、12个月,两组TC、TG、LDL-C均较治疗前显著降低,而HDL-C水平较治疗前显著升高(P0.05);A组TC、TG、LDL-C水平显著低于B组,而HDL-C水平显著高于B组(P0.05);治疗后6、12个月,两组hs-CRP、Hcy、TNF-α、IMT水平均较治疗前显著降低(P0.05);且A组hs-CRP、Hcy、TNF-α、IMT水平显著低于B组(P0.05);两组肱动脉内径均无明显变化(P0.05),而血流介导内皮依赖性舒张功能(FMD)水平均较治疗前显著升高(P0.05),且A组升高程度显著高于B组(P0.05);两组不良反应发生率无显著差异(P0.05)。结论瑞舒伐他汀与阿托伐他汀均可有效改善老年冠心病患者的血脂水平、降低患者hsCRP、Hcy、IMT及TNF-α水平,并显著改善患者血管内皮功能,且瑞舒伐他汀临床效果更佳。
[Abstract]:Objective to compare the effects of rosuvastatin and Atto vastatin on serum lipids, hypersensitive C-reactive protein hs-CRP, homocysteine cystatin and carotid intima-media thickness in elderly patients with coronary heart disease. Methods 127 elderly patients with coronary heart disease were randomly divided into group A (n = 65) and group B (n = 62) treated with Atto vastatin. Six and twelve months after treatment, the changes of total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), hs-CRPcyclin, tumor necrosis factor (TNF- 伪) IMT and vascular endothelial function were recorded, and the adverse drug related reactions during the treatment were recorded. Results at 6 and 12 months after treatment, the levels of TCU TGN LDL-C in both groups were significantly lower than those before treatment, while the level of HDL-C in group A was significantly lower than that in group B, and the level of HDL-C in group A was significantly higher than that in group B (P 0.05), and the level in group A was significantly higher than that in group A (P 0.05). The levels of hs-CRPU HcyTNF- 伪 IMT in both groups were significantly lower than those before treatment, and the levels of hs-CRPU TNF- 伪 IMT in group A were significantly lower than those in group B (P 0.05). The brachial artery diameter in both groups had no significant change (P0.05), while the level of blood flow mediated endothelium-dependent diastolic function (FMDs) was significantly higher than that before treatment, and the level of FMDs was significantly higher in group A than that in group B (P 0.05), and there was no significant change in brachial artery diameter in both groups (P 0.05). The elevated degree in group A was significantly higher than that in group B (P 0.05), and there was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). Conclusion Risuvastatin and Atto vastatin can effectively improve the serum lipid level, decrease the levels of hsCRP- Hcyimt and TNF- 伪 in elderly patients with coronary heart disease, and significantly improve the vascular endothelial function of the patients, and the clinical effect of recuvastatin is better.
【作者单位】：浙江新安国际医院心血管内科;
【分类号】：R541.4

【相似文献】